Vericel Corp (VCEL) Hits New High on Drug Data

Vericel Corp's (NASDAQ:VCEL) heart failure treatment met its main goals in a Phase 2 study

Mar 11, 2016 at 1:17 PM
facebook twitter linkedin


Cellular therapy stock Vericel Corp (NASDAQ:VCEL) exploded for an 86.3% gain on Thursday, with trading volume reaching an annual high, after the company announced that its heart failure treatment candidate met its main goals in a Phase 2 study. VCEL plans to give more information about the trial on Monday, April 4. The shares have added another 5.8% today to trade at $4.18, and earlier hit an annual high of $5.18. In the meantime, the stock has seen a rare dose of option trading. 

There's usually next to no activity in VCEL's option pits, but that's changed over the past two days. Yesterday, over 1,000 calls crossed, with much of the activity occurring at the March 5 call -- where it's likely long positions were added. Another 1,000 calls have been traded in today's session, and it looks like traders may have liquidated their VCEL March 5 calls, taking profits on the earlier move above $5. 

Despite the positive development, many speculators may be hesitant to place bullish bets on Vericel Corp (NASDAQ:VCEL), given its technical track record. The 10-year chart below should tell the whole story:

160311VCEL

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners